| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 76,04 | 76,18 | 10.08. | |
| 75,91 | 76,01 | 10.08. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 76,12 | 89 | |||
| 75,75 | 155 | |||
| 75,70 | 54 | |||
| 75,69 | 9 | |||
| 75,68 | 54 | |||
| 75,66 | 216 | |||
| 75,63 | 327 | |||
| 75,61 | 67 | |||
| 75,60 | 440 | |||
| 75,57 | 332 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/snw.htm [/URL] | ||||
| 108 | 75,50 | |||
| 332 | 75,44 | |||
| 548 | 75,41 | |||
| 54 | 75,39 | |||
| 305 | 75,38 | |||
| 54 | 75,37 | |||
| 135 | 74,83 | |||
| 25 | 74,10 | |||
| 50 | 73,60 | |||
| 50 | 72,95 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.661 | 1,049 | 1.743 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:46 | 75,56 | 147 |
| 17:24:27 | 75,51 | 1 |
| 17:24:27 | 75,52 | 30 |
| 17:23:32 | 75,52 | 89 |
| 17:23:16 | 75,51 | 70 |
| 17:21:29 | 75,52 | 84 |
| 17:20:46 | 75,57 | 105 |
| 17:20:46 | 75,57 | 160 |
| 17:19:09 | 75,60 | 3 |
| 17:17:16 | 75,53 | 1 |
| 17:16:37 | 75,59 | 68 |
| 17:16:09 | 75,55 | 46 |
| 17:06:36 | 75,52 | 154 |
| 16:49:21 | 75,31 | 61 |
| 16:47:03 | 75,38 | 800 |
| 16:42:13 | 75,34 | 80 |
| 16:42:13 | 75,34 | 24 |
| 16:38:38 | 75,33 | 12 |
| 16:36:55 | 75,27 | 18 |
| 16:27:47 | 75,33 | 221 |
| Tagesumsatz Xetra | +0,22 +0,29 % | 6.954 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:26 | Why the Amlitelimab Setback Isn't Enough to Sink Sanofi's Multi-Billion Dollar Engine | 4 | Insider Monkey | ||
| Fr | JEFFERIES stuft SANOFI auf 'Buy' | 659 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Sanofi mit einem Kursziel von 100 Euro auf "Buy" belassen. Analyst Michael Leuchten passte seine Schätzungen am Donnerstag... ► Artikel lesen | |
| SANOFI Aktie jetzt für 0€ handeln | |||||
| Do | KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments | 11 | Zacks | ||
| Do | Sanofi asked to change Dupixent ads after Galderma challenge | 17 | FiercePharma | ||
| Do | Antipodes Exited Sanofi (SNY) After Repeated Pipeline Setbacks | 14 | Insider Monkey |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mo | Novo Nordisk A/S: Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI | GlobeNewswire (Europe) | New AI co-innovation hub in London brings together AWS engineers, AI specialists, and applied scientists alongside Novo Nordisk research and development teams to increase productivity and help reduce... ► Artikel lesen | |
| Mo | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue | ACCESS Newswire | Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterpriseAdds an established global brand with scale in large... ► Artikel lesen | |
| Mo | JEFFERIES stuft BAYER AG auf 'Hold' | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Bayer nach Zahlen zum zweiten Quartal auf "Hold" mit einem Kursziel von 46 Euro belassen. Analyst Michael Leuchten nahm... ► Artikel lesen | |
| Mo | Wave Life Sciences Ltd.: Wave Life Sciences Announces Completion of Redomiciliation to Delaware | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform... ► Artikel lesen | |
| Mo | DataMEDS AI, Inc.: DataMeds AI Renames Pharmacy Subsidiaries Corexa Pharmacy and Corexa Tech & Hub Under New Corexa Health Division | ACCESS Newswire | TAMPA, FL / ACCESS Newswire / August 10, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx... ► Artikel lesen |